First-of-its-kind pill targets a mutation that fuels more than 90% of pancreatic cancers.

The therapy is a brand new targeted drug for the disease which experts have labelled as a substantial breakthrough following doubling of survival time in a trial.

U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer.